Indefinite Delivery Contract SPM2DX14D0973

This indefinite delivery contract (IDC) was awarded by the U.S. Defense Logistics Agency (DLA) to the woman-owned small business DMS Pharmaceutical Group Inc. The single-award IDC, valued up to $499,999,999, provides the DLA with a comprehensive range of pharmaceutical items to fulfill the recurring medical supply needs of military health facilities worldwide. Through this IDC vehicle, DMS Pharmaceutical Group supplies both routine and critical medications, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support diverse medical requirements across various Department of Defense healthcare facilities. The IDC, which runs through December 31, 2025, is complemented by DMS Pharmaceutical Group's separate prime vendor contracts for direct distribution of prescription drugs and pharmacy services to DoD sites, solidifying the company's position as a crucial supplier in the federal pharmaceutical supply chain.

The task orders under this IDC cover a wide array of pharmaceutical products, from common medications like antibiotics, pain relievers, and cardiovascular drugs, to specialized drugs such as flumazenil injections, prednisone tablets, ampicillin injections, clotrimazole cream, epinephrine auto-injectors, contraceptives, oncology drugs, and specialty medications. These firm fixed-price delivery orders, which have no set-aside designations, are primarily fulfilled from DMS Pharmaceutical Group's facilities in Park Ridge, Illinois. The IDC and associated task orders aim to provide the DLA and military health facilities with a reliable and comprehensive source of pharmaceutical items to support the diverse medical needs of U.S. armed forces personnel and their dependents.